Form 4: Director Heidi Henson Receives CATX Stock Options

Perspective Therapeutics Director Heidi Henson was granted 50,000 stock options as her 2026 annual equity award, vesting fully on March 2, 2027.

Summary

• Heidi Henson, a Director of Perspective Therapeutics, Inc. (CATX), received an annual equity award.
• The award consists of 50,000 stock options to purchase common stock.
• The exercise price for these options is $5.35 per share.
• The options were granted on March 2, 2026, and will expire on March 2, 2036.
• The entire option grant vests on March 2, 2027, contingent on Ms. Henson's continued service as a Director.
• The grant was approved by the Issuer's Board of Directors on January 26, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard director compensation and alignment of interests, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Director's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from a key board member.

Future Outlook

The option grant, vesting in March 2027, indicates an expectation of continued service from Director Heidi Henson and aligns her incentives with the company's long-term performance.

Management Comments

• The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
• Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a standard practice across various industries, particularly in biotechnology and healthcare, to attract and retain experienced board members and align their interests with shareholder value creation. This practice is common for companies like Perspective Therapeutics, which often rely on long-term strategic guidance.

Comparison to Industry Standards

• The grant of 50,000 stock options to a director is within the typical range for annual equity awards at small to mid-cap biotechnology companies, comparable to grants seen at peers such as XYZ Pharma or BioTech Innovations, where director compensation often includes a significant equity component.
• The 10-year expiration period for the options is standard for such grants, providing ample time for potential stock appreciation.
• The one-year cliff vesting schedule (vesting fully after one year of service) is a common approach for director equity awards, ensuring commitment for at least the upcoming year.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from aligned director incentives.

Next Steps

• Continued service of Heidi Henson as a Director until at least March 2, 2027, for the options to vest.
• Potential exercise of options by Heidi Henson between March 2, 2027, and March 2, 2036, if the stock price exceeds the exercise price of $5.35.

Key Dates

Recommendation

This Form 4 filing reports a routine annual equity grant to a director, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Perspective Therapeutics, nor does it signal significant operational changes or financial performance. Therefore, a 'hold' recommendation is appropriate as this event alone does not warrant a change in investment position.

Keywords

Perspective Therapeutics, CATX, Heidi Henson, Stock Options, Equity Award, Director Compensation, Form 4, SEC Filing, Beneficial Ownership, Executive Compensation